AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
Log in

NASDAQ:RAREUltragenyx Pharmaceutical Competitors & Alternatives

$90.00
+2.12 (+2.41 %)
(As of 07/8/2020 04:00 PM ET)
Add
Compare
Today's Range
$87.81
Now: $90.00
$91.77
50-Day Range
$66.46
MA: $73.84
$86.04
52-Week Range
$31.99
Now: $90.00
$91.77
Volume391,772 shs
Average Volume582,346 shs
Market Capitalization$5.37 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.28

Competitors

Ultragenyx Pharmaceutical (NASDAQ:RARE) Vs. ALNY, BGNE, GLPG, GRFS, SRPT, and TEVA

Should you be buying RARE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Ultragenyx Pharmaceutical, including Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), GALAPAGOS NV/S (GLPG), GRIFOLS S A/S (GRFS), Sarepta Therapeutics (SRPT), and Teva Pharmaceutical Industries (TEVA).

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Valuation & Earnings

This table compares Ultragenyx Pharmaceutical and Alnylam Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$103.71 million51.77$-402,730,000.00($7.36)-12.23
Alnylam Pharmaceuticals$219.75 million84.21$-886,120,000.00($8.11)-19.78

Ultragenyx Pharmaceutical has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Ultragenyx Pharmaceutical and Alnylam Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ultragenyx Pharmaceutical031302.81
Alnylam Pharmaceuticals131402.72

Ultragenyx Pharmaceutical currently has a consensus price target of $81.3571, indicating a potential downside of 9.60%. Alnylam Pharmaceuticals has a consensus price target of $151.2778, indicating a potential downside of 5.70%. Given Alnylam Pharmaceuticals' higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Ultragenyx Pharmaceutical.

Profitability

This table compares Ultragenyx Pharmaceutical and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ultragenyx Pharmaceutical-348.78%-60.65%-40.51%
Alnylam Pharmaceuticals-310.01%-57.63%-35.70%

Volatility & Risk

Ultragenyx Pharmaceutical has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500.

Institutional & Insider Ownership

99.9% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 93.4% of Alnylam Pharmaceuticals shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 3.5% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Beigene (NASDAQ:BGNE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Valuation & Earnings

This table compares Ultragenyx Pharmaceutical and Beigene's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$103.71 million51.77$-402,730,000.00($7.36)-12.23
Beigene$428.21 million37.07$-948,630,000.00($15.80)-12.92

Ultragenyx Pharmaceutical has higher earnings, but lower revenue than Beigene. Beigene is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Ultragenyx Pharmaceutical and Beigene, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ultragenyx Pharmaceutical031302.81
Beigene04702.64

Ultragenyx Pharmaceutical currently has a consensus price target of $81.3571, indicating a potential downside of 9.60%. Beigene has a consensus price target of $202.8111, indicating a potential downside of 0.63%. Given Beigene's higher probable upside, analysts clearly believe Beigene is more favorable than Ultragenyx Pharmaceutical.

Profitability

This table compares Ultragenyx Pharmaceutical and Beigene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ultragenyx Pharmaceutical-348.78%-60.65%-40.51%
Beigene-284.45%-68.64%-47.15%

Volatility & Risk

Ultragenyx Pharmaceutical has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500. Comparatively, Beigene has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500.

Institutional & Insider Ownership

99.9% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 63.8% of Beigene shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 11.0% of Beigene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Ultragenyx Pharmaceutical beats Beigene on 9 of the 14 factors compared between the two stocks.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and GALAPAGOS NV/S (NASDAQ:GLPG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Valuation and Earnings

This table compares Ultragenyx Pharmaceutical and GALAPAGOS NV/S's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$103.71 million51.77$-402,730,000.00($7.36)-12.23
GALAPAGOS NV/S$1.00 billion13.13$167.83 million$5.4636.99

GALAPAGOS NV/S has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than GALAPAGOS NV/S, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Ultragenyx Pharmaceutical has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Comparatively, GALAPAGOS NV/S has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

Profitability

This table compares Ultragenyx Pharmaceutical and GALAPAGOS NV/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ultragenyx Pharmaceutical-348.78%-60.65%-40.51%
GALAPAGOS NV/S15.42%12.45%6.07%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Ultragenyx Pharmaceutical and GALAPAGOS NV/S, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ultragenyx Pharmaceutical031302.81
GALAPAGOS NV/S27702.31

Ultragenyx Pharmaceutical currently has a consensus price target of $81.3571, suggesting a potential downside of 9.60%. GALAPAGOS NV/S has a consensus price target of $229.00, suggesting a potential upside of 13.38%. Given GALAPAGOS NV/S's higher probable upside, analysts plainly believe GALAPAGOS NV/S is more favorable than Ultragenyx Pharmaceutical.

Institutional and Insider Ownership

99.9% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 11.7% of GALAPAGOS NV/S shares are owned by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 2.9% of GALAPAGOS NV/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

GALAPAGOS NV/S beats Ultragenyx Pharmaceutical on 8 of the 14 factors compared between the two stocks.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and GRIFOLS S A/S (NASDAQ:GRFS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Valuation and Earnings

This table compares Ultragenyx Pharmaceutical and GRIFOLS S A/S's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$103.71 million51.77$-402,730,000.00($7.36)-12.23
GRIFOLS S A/S$5.71 billion2.24$700.16 million$1.1715.89

GRIFOLS S A/S has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than GRIFOLS S A/S, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Ultragenyx Pharmaceutical has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Comparatively, GRIFOLS S A/S has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Profitability

This table compares Ultragenyx Pharmaceutical and GRIFOLS S A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ultragenyx Pharmaceutical-348.78%-60.65%-40.51%
GRIFOLS S A/S13.31%11.92%4.91%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Ultragenyx Pharmaceutical and GRIFOLS S A/S, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ultragenyx Pharmaceutical031302.81
GRIFOLS S A/S13602.50

Ultragenyx Pharmaceutical currently has a consensus price target of $81.3571, suggesting a potential downside of 9.60%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, research analysts plainly believe Ultragenyx Pharmaceutical is more favorable than GRIFOLS S A/S.

Institutional and Insider Ownership

99.9% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 17.9% of GRIFOLS S A/S shares are owned by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Valuation and Earnings

This table compares Ultragenyx Pharmaceutical and Sarepta Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$103.71 million51.77$-402,730,000.00($7.36)-12.23
Sarepta Therapeutics$380.83 million34.84$-715,080,000.00($9.71)-17.52

Ultragenyx Pharmaceutical has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Ultragenyx Pharmaceutical has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500.

Profitability

This table compares Ultragenyx Pharmaceutical and Sarepta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ultragenyx Pharmaceutical-348.78%-60.65%-40.51%
Sarepta Therapeutics-160.96%-64.67%-31.92%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Ultragenyx Pharmaceutical and Sarepta Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ultragenyx Pharmaceutical031302.81
Sarepta Therapeutics012302.96

Ultragenyx Pharmaceutical currently has a consensus price target of $81.3571, suggesting a potential downside of 9.60%. Sarepta Therapeutics has a consensus price target of $198.9091, suggesting a potential upside of 16.90%. Given Sarepta Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Institutional and Insider Ownership

99.9% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 93.1% of Sarepta Therapeutics shares are owned by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Ultragenyx Pharmaceutical beats Sarepta Therapeutics on 8 of the 14 factors compared between the two stocks.

Teva Pharmaceutical Industries (NYSE:TEVA) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Institutional and Insider Ownership

48.8% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 99.9% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Teva Pharmaceutical Industries and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teva Pharmaceutical Industries-4.73%18.10%4.72%
Ultragenyx Pharmaceutical-348.78%-60.65%-40.51%

Analyst Recommendations

This is a summary of current ratings and target prices for Teva Pharmaceutical Industries and Ultragenyx Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teva Pharmaceutical Industries412602.09
Ultragenyx Pharmaceutical031302.81

Teva Pharmaceutical Industries currently has a consensus target price of $11.50, suggesting a potential upside of 0.88%. Ultragenyx Pharmaceutical has a consensus target price of $81.3571, suggesting a potential downside of 9.60%. Given Teva Pharmaceutical Industries' higher possible upside, equities analysts plainly believe Teva Pharmaceutical Industries is more favorable than Ultragenyx Pharmaceutical.

Risk & Volatility

Teva Pharmaceutical Industries has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.28, suggesting that its share price is 128% more volatile than the S&P 500.

Valuation & Earnings

This table compares Teva Pharmaceutical Industries and Ultragenyx Pharmaceutical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$16.89 billion0.74$-998,000,000.00$2.314.94
Ultragenyx Pharmaceutical$103.71 million51.77$-402,730,000.00($7.36)-12.23

Ultragenyx Pharmaceutical has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Summary

Ultragenyx Pharmaceutical beats Teva Pharmaceutical Industries on 8 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.5$160.42+0.3%$18.65 billion$219.75 million-19.98
Beigene logo
BGNE
Beigene
1.1$204.10+3.7%$15.30 billion$428.21 million-11.58Insider Selling
GALAPAGOS NV/S logo
GLPG
GALAPAGOS NV/S
1.2$201.97+0.3%$13.13 billion$1.00 billion79.52
GRIFOLS S A/S logo
GRFS
GRIFOLS S A/S
1.4$18.59+0.6%$13.10 billion$5.71 billion16.60Increase in Short Interest
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.7$170.15+3.7%$12.98 billion$380.83 million-19.27
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$11.40+1.7%$12.16 billion$16.89 billion-15.00
Catalent logo
CTLT
Catalent
1.1$76.22+3.3%$11.39 billion$2.52 billion108.89
Horizon Therapeutics logo
HZNP
Horizon Therapeutics
1.7$58.76+2.5%$11.09 billion$1.30 billion20.76Insider Selling
Heavy News Reporting
Dr.Reddy's Laboratories logo
RDY
Dr.Reddy's Laboratories
0.9$52.26+1.5%$8.67 billion$2.32 billion31.87Analyst Downgrade
Heavy News Reporting
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.5$21.65+0.5%$8.63 billion$3.07 billion-1,082.50
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$61.39+1.0%$8.56 billion$1.12 billion55.81
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.5$56.40+1.1%$8.37 billion$339.08 million-35.70Analyst Upgrade
Mylan logo
MYL
Mylan
1.6$16.19+0.5%$8.33 billion$11.50 billion134.93
Perrigo logo
PRGO
Perrigo
1.9$55.20+0.2%$7.54 billion$4.84 billion40.29
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.7$147.60+2.9%$7.29 billion$14.98 million-27.69
Bausch Health Companies logo
BHC
Bausch Health Companies
2.5$17.55+5.0%$6.37 billion$8.60 billion-3.27Analyst Report
Increase in Short Interest
Heavy News Reporting
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
3.0$107.54+1.2%$6.15 billion$2.16 billion22.36Increase in Short Interest
SDGR
PPD
0.9$87.09+7.0%$5.90 billion$85.54 million0.00
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$158.00+1.5%$5.33 billion$26.52 million-16.06
United Therapeutics logo
UTHR
United Therapeutics
1.7$117.78+0.7%$5.24 billion$1.45 billion9.82Analyst Downgrade
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
0.9$119.00+1.4%$5.08 billion$3.34 million-18.34
Zai Lab logo
ZLAB
Zai Lab
1.1$86.87+4.7%$4.78 billion$12.98 million-28.67Analyst Report
Heavy News Reporting
Emergent Biosolutions logo
EBS
Emergent Biosolutions
1.4$94.41+5.2%$4.69 billion$1.11 billion72.62Heavy News Reporting
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.4$45.25+2.2%$4.58 billion$168.80 million502.83
Myokardia logo
MYOK
Myokardia
1.4$95.29+1.3%$4.44 billion$33.56 million-14.29Insider Selling
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.6$78.66+1.9%$4.30 billion$66.51 million-10.59Insider Selling
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.3$72.08+0.7%$4.28 billionN/A-5.71
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.8$24.78+2.6%$4.27 billion$114.62 million-9.49
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.6$68.35+2.1%$4.12 billion$2.11 million-14.03Analyst Downgrade
Increase in Short Interest
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$15.78+0.7%$4.10 billion$182.24 million-12.14Insider Selling
GW Pharmaceuticals PLC- logo
GWPH
GW Pharmaceuticals PLC-
1.6$129.00+0.5%$4.00 billion$311.33 million131.63Insider Selling
HUTCHISON CHINA/S logo
HCM
HUTCHISON CHINA/S
1.0$29.28+1.0%$3.81 billion$204.89 million-36.60
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.6$54.86+1.0%$3.78 billion$117.91 million-9.35
FibroGen logo
FGEN
FibroGen
2.1$41.91+0.6%$3.71 billion$256.58 million-31.75
ChemoCentryx logo
CCXI
ChemoCentryx
1.5$61.69+4.7%$3.64 billion$36.13 million-56.60Insider Selling
Unusual Options Activity
BBIO
BridgeBio Pharma
1.6$30.42+2.5%$3.60 billion$40.56 million-12.27Insider Selling
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.1$57.07+3.6%$3.54 billion$306.98 million-11.44Insider Selling
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$63.80+0.5%$3.24 billion$806.43 million-9.88
Allakos logo
ALLK
Allakos
1.1$68.86+2.1%$3.24 billionN/A-34.60Analyst Downgrade
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
2.2$83.88+2.2%$3.13 billionN/A-32.77Heavy News Reporting
Alkermes logo
ALKS
Alkermes
1.1$20.41+1.6%$3.12 billion$1.17 billion-23.19
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.5$56.80+3.3%$3.08 billion$25 million-12.59Analyst Downgrade
Insider Selling
Increase in Short Interest
Heavy News Reporting
Insmed logo
INSM
Insmed
1.5$28.39+2.6%$2.90 billion$136.47 million-10.07Analyst Upgrade
KRTX
Karuna Therapeutics
1.5$100.18+0.7%$2.64 billionN/A-0.68Increase in Short Interest
Opko Health logo
OPK
Opko Health
1.7$4.08+6.1%$2.63 billion$901.90 million-8.50Analyst Report
Increase in Short Interest
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.4$65.81+1.7%$2.61 billion$644.77 million10.35Decrease in Short Interest
Amarin logo
AMRN
Amarin
1.8$6.77+0.4%$2.59 billion$429.76 million-112.83
TG Therapeutics logo
TGTX
TG Therapeutics
1.7$23.86+5.2%$2.49 billion$150,000.00-11.75Analyst Downgrade
Heavy News Reporting
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.7$30.97+0.5%$2.33 billionN/A-4.93Increase in Short Interest
Heavy News Reporting
Pacira Biosciences logo
PCRX
Pacira Biosciences
1.4$56.54+4.2%$2.29 billion$421.03 million-2,825.59Analyst Report
High Trading Volume
This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.